Research programme: serotonin 2a antagonists - Arena PharmaceuticalsAlternative Names: G-protein coupled receptors-cardiovascular therapies research programme - Arena Pharmaceuticals
Latest Information Update: 02 Aug 2005
At a glance
- Originator Arena Pharmaceuticals
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Arterial thrombosis
Most Recent Events
- 02 Aug 2005 This programme is still in active development - (BIO-2005)
- 02 Mar 2004 Preclinical trials in Thrombosis in USA (unspecified route)